MichaelDHogartyMD
Pediatric Hematology & Oncology • Philadelphia, PAAssociate Professor, Pediatrics, Perelman School of Medicine
Are you Dr. Hogarty?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 68 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
3401& Civic Center Blvd
Children's Hospital Of Philadelphia - Hem/Onc
Philadelphia, PA 19104Phone+1 215-590-3535Fax+1 215-590-3992
Summary
- Dr. Michael Hogarty, MD is a pediatric hematologist/oncologist in Philadelphia, Pennsylvania. He is currently licensed to practice medicine in Pennsylvania and Illinois. He is affiliated with Children's Hospital of Philadelphia and is an Associate Professor at Perelman School of Medicine.
Education & Training
Children's Hospital of PhiladelphiaFellowship, Pediatric Hematology/Oncology, 1994 - 1997
McGaw Medical Center of Northwestern UniversityResidency, Pediatrics, 1990 - 1994
Columbia University Vagelos College of Physicians and SurgeonsClass of 1990
Certifications & Licensure
PA State Medical License 1994 - 2024
IL State Medical License 1990 - 1996- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- Study of DNA in Blood Samples From Patients With Neuroblastoma Start of enrollment: 2007 Jun 01
- Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma Start of enrollment: 2000 Nov 06
- Study of Specimens From Young Patients With Neuroblastoma Start of enrollment: 2008 Dec 01
Publications & Presentations
PubMed
- 90 citationsPreclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma.Babak Moghimi, Sakunthala Muthugounder, Samy Jambon, Rachelle Tibbetts, Long Hung
Nature Communications. 2021-01-21 - 326 citationsIntegrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma.Mark Sausen, Rebecca J. Leary, Siân Jones, Jian Wu, C. Patrick Reynolds
Nature Genetics. 2013-01-01 - 258 citationsALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastomaScott C. Bresler, Daniel A. Weiser, Peter J. Huwe, Jin H. Park, Kateryna Krytska
Cancer Cell. 2014-11-10
Press Mentions
- CHOP Researchers Uncover Unique Mechanism for Cancer Therapy ResistanceApril 1st, 2022
- Panbela Announces Publication of Clinical Data Titled: Phase 1 Study of High-Dose DFMO, Celecoxib, Cyclophosphamide and Topotecan for Patients with Relapsed Neuroblastoma: A New Approaches to Neuroblastoma Therapy TrialJanuary 23rd, 2024
